Bellmunt风险评分可预测接受PSMA靶向放射配体治疗的转移性去势抵抗性前列腺癌男性患者的生存
本研究回顾性纳入386例在本中心接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,评估Bellmunt风险评分(BRS)对总生存(OS)的预测价值。BRS是多变量分析中OS的独立预测因子,评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。加入C反应蛋白(CRP)的增强版评分可进一步提高预后准确性。
要点
- BRS是多变量分析中mCRPC患者接受[177Lu]Lu-PSMA-617治疗后OS的独立预测因子。
- BRS评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
- BRS预测1年和2年OS的tAUC分别为71.6%和74.4%,CRP增强版评分分别达75.7%和78.1%。
核心结论
- Bellmunt风险评分能有效对接受[177Lu]Lu-PSMA-617治疗的mCRPC患者进行风险分层。
- 该评分设计简单,基于易获取的临床参数,在真实临床环境中具有实用性和应用价值。
研究设计与样本
- 回顾性评估386例在本中心接受[177Lu]Lu-PSMA-617治疗的mCRPC患者数据。
- BRS的构建:ECOG体能状态(ECOG PS)> 0、血红蛋白 < 10 g/dL、存在肝转移,每项危险因素计1分。
- 另开发了纳入C反应蛋白(CRP)> 30 mg/dL的增强版评分和使用半定量ECOG PS的改良版评分。
- 统计分析包括Cox回归、Kaplan-Meier估计、一致性指数和时间依赖AUC(tAUC)。
主要发现
- BRS是多变量分析中OS的独立预测因子。
- BRS评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
- BRS预测1年和2年OS的tAUC分别为71.6%和74.4%。
- CRP增强版评分进一步提高预后准确性,预测1年OS的tAUC为75.7%,2年OS的tAUC为78.1%。
关键数值与推荐
- BRS危险因素:ECOG PS > 0、血红蛋白 < 10 g/dL、存在肝转移,每项计1分。
- CRP增强版评分额外纳入CRP > 30 mg/dL。
- BRS评分0、1、2、3分对应的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
- BRS预测1年和2年OS的tAUC分别为71.6%和74.4%;CRP增强版评分分别为75.7%和78.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [177Lu]Lu-PSMA-617 therapy has emerged as a promising radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). Given the overall poor prognosis of mCRPC, accurately predicting the key endpoint overall survival (OS) remains an ongoing challenge, crucial for optimizing risk/benefit assessment prior to treatment. This study investigates the prognostic utility of the simple designed Bellmunt Risk Score (BRS) in mCRPC patients treated with [177Lu]Lu-PSMA-617. METHODS: We retrospectively evaluated data from 386 mCRPC patients who had received [177Lu]Lu-PSMA-617 therapy at our center. BRS was constructed by attributing one point for each of the following risk factors: ECOG performance status (ECOG PS) > 0, hemoglobin < 10 g/dL, and the presence of liver metastases. Additionally, an enhanced version of the score including C-reactive protein (CRP) > 30 mg/dL and a modified version utilizing a semi-quantitative ECOG PS were developed. Statistical analysis included Cox regression, Kaplan-Meier estimates, concordance indices and time-dependent area under the curve (tAUC). RESULTS: The BRS served as an independent predictor of OS in multivariable analysis. The estimated median OS was 17.6, 10.9, 6.6, and 2.7 months for patients with scores of 0, 1, 2 and 3, respectively (Log-Rank P < 0.001). The tAUC values for predicting 1-year and 2-year OS were 71.6% and 74.4%, respectively. The CRP-enhanced score further improved prognostic accuracy, achieving tAUCs of 75.7% for 1-year OS and 78.1% for 2-year OS. CONCLUSION: The Bellmunt Risk Score effectively stratifies mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. Its straightforward design, based on readily accessible clinical parameters, ensures practicality and utility in real-world clinical settings.
引用
- Büttner T, Marinova M, Gaertner FC, et al. Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). Eur J Nucl Med Mol Imaging. 2025. PMID: 40751808. doi:10.1007/s00259-025-07492-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。